Work

Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia

Year: 2018

Type: article

Study design: Clinical Trial

Abstract: Key Points In a pilot study, the nonanticoagulant heparin derivative CX-01 was well tolerated when combined with chemotherapy for the treatment of AML. Preliminary results show encouraging complete remission rates and rapid platelet recovery.

Source: Blood Advances

DOI: 10.1182/bloodadvances.2017013391

Authors: Tibor J. Kovacsovics, Alice Mims, Mohamed E. Salama, Jeremy Pantin, Narayanam Rao, Ken M. Kosak, Peter Ahorukomeye, Martha J. Glenn, Michael W. N. Deininger, Kenneth M. Boucher, Linda M. Bavisotto, Gerardo Gutierrez-Sanchez, Thomas P. Kennedy, Stephen G. Marcus, Paul J. Shami

Institutions: University of Utah, Huntsman Cancer Institute, Medical University of South Carolina, MUSC Hollings Cancer Center, Augusta University, University of Georgia, Wake Forest University

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,800

Funder: National Cancer Institute

Award: G368171078

OpenAlex ID: W2792228267

FWCI: 4.711

Cites: 41

Cited by: 57

Related to: 10